Format

Send to

Choose Destination
Chemotherapy. 2010;56(3):184-9. doi: 10.1159/000316328. Epub 2010 Jun 10.

In vitro activity of tigecycline and other tetracyclines against carbapenem-resistant Acinetobacter species: report from a tertiary care centre in Karachi, Pakistan.

Author information

1
Department of Clinical Microbiology, Aga Khan University Hospital, Karachi, Pakistan. sadia.shakkoor @ aku.edu

Abstract

BACKGROUND:

The Aga Khan University Hospital is a tertiary care centre in Karachi, Pakistan, where tigecycline has not been used previously. We report findings of a pre-use in vitro study to evaluate sensitivity of nosocomial Acinetobacter spp. Tigecycline minimum inhibitory concentration (MIC) was correlated with that of other tetracyclines to assess their predictive potential.

METHODS:

Acinetobacter spp. were collected from hospitalized inpatients admitted to Aga Khan University Hospital from April to November 2007. Tigecycline, tetracycline, doxycycline, and minocycline MICs were determined by E-test.

RESULTS:

One hundred isolates of Acinetobacter spp. were tested. Ninety-eight percent of Acinetobacter spp. were carbapenem-resistant. Tigecycline MIC(50) and MIC(90) were 1.5 and 2.0 microg/ml, respectively. Unavailability of standard breakpoints hindered categorization of these values. Minocycline was highly active, with MIC(90) of 2.0 microg/ml.

CONCLUSIONS:

Tigecycline breakpoints for Acinetobacter spp. should be established to prevent injudicious use of this antibiotic based on misleading in vitro results. The therapeutic potential of minocycline needs more in-depth study.

PMID:
20551633
DOI:
10.1159/000316328
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center